If you have wet age-related macular degeneration (wet AMD) or another disease of the retina, your doctor may recommend treatment with an anti-VEGF drug. VEGF, or vascular endothelial growth factor, is ...

STOCKHOLM — A real-world analysis of retrospective data showed that administering more anti-VEGF injections over a 5-year time span to treat macular edema secondary to retinal vein occlusion (RVO) was ...

Longer-term follow-up of a randomized trial confirmed that prophylactic anti-VEGF therapy with aflibercept (Eylea) slows progression of diabetic retinopathy but does not improve visual acuity better ...

In the study, researchers found that nearly one-quarter of anti-VEGF injections were received at least 1 week later than intended. Christina Y. Weng, MD, MBA, and colleagues compared the intended ...

Severe, long-standing DME with cystoid changes, subretinal detachment, and high inflammatory cytokine burden tends to respond better to dual ANG2/VEGF-A inhibition than VEGF monotherapy. Faricimab ...

Masking during intravitreal anti-VEGF injections was associated with a similar incidence of endophthalmitis compared to not masking, in a large retrospective study. After adjusting for the use of ...

Migaldendranib (MGB) is a new class of targeted nanomedicine for the treatment of diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) with a novel mechanism of action ...

A new study in mice suggests experimental eye drops may be more effective than injections for treatment of retinal vein occlusion, a major cause of blindness. A new study suggests that eye drops ...